主页 > 医学文档 >
【商业翻译】(医师报约稿)Immediate Treatment Of Ear
2.本星期三（5.16）晚上十点前交稿
3.格式见置顶的文摘编译格式：http://www.dxy.cn/bbs/post/view?bid=116&id=8600034&sty=1&tpg=1&age=0
4.稿酬按医师报标准
5.为保证翻译质量起见，在本版得分超过15分以上的战友方可认领
6.每位战友最多认领2篇,编译群战友可根据自己的专业和精力，最多认领3篇
7.作者统一署名为"丁香"
8.质量第一，切切
Immediate Treatment Of Early MS Patients With Betaferon® Significantly Delayed Permanent Disability
Bayer Schering Pharma AG, Germany, announced today new data, which show that immediate initiation of Betaferon® (interferon beta-1b) treatment in patients with a first event suggestive of multiple sclerosis (MS) can significantly reduce the risk of permanent neurological impairment as measured by the Expanded Disability Status Scale (EDSS) by 40 percent over three years compared to delayed treatment. These findings from the BENEFIT (BEtaferon in Newly Emerging multiple sclerosis For Initial Treatment) studies* were presented today at the American Academy of Neurology's 59th Annual Meeting in Boston, Massachusetts.
"Some patients have already developed significant neurological damage when they first present with signs of MS, which can lead to accumulated disability later in life. The BENEFIT results clearly show that immediate treatment with Betaferon® initiated after the first clinical event can significantly reduce that damage, which could translate into a greater delay in the time it takes for patients to suffer from the debilitating consequences of MS," said Dr. Mark S. Freedman, Professor of Neurology at the University of Ottawa and investigator of the study. "This is a truly novel finding that has not yet been demonstrated for any other immunomodulatory MS treatment, and underscores the urgent need to treat patients early rather than waiting for further signs of MS to develop. Physicians and patients should consider these unprecedented findings when making treatment decisions."
"Immediate treatment" refers to treatment initiated after the first clinical event; "delayed treatment" is initiated after the second clinical event or after 2 years, whatever comes first.
"We are delighted that the BENEFIT study continues to deliver ground-breaking results," said Darlene Jody, M.D., President of Bayer HealthCare's Specialized Therapeutics Global Business Unit. "In the past year, Betaferon® has received approval around the world for use in patients with the earliest signs of MS. We intend to submit this novel data for inclusion in our label. Regulatory approval would further differentiate Betaferon® from other products in the market place and strengthen our position." 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Immediate Treatment Of Early MS Patients With Betaferon® Significantly Delayed Permanent Disability
对早期多发性硬化症患者使用倍泰龙将明显延缓永久性残疾
Bayer Schering Pharma AG, Germany, announced today new data, which show that immediate initiation of Betaferon® (interferon beta-1b) treatment in patients with a first event suggestive of multiple sclerosis (MS) can significantly reduce the risk of permanent neurological impairment as measured by the Expanded Disability Status Scale (EDSS) by 40 percent over three years compared to delayed treatment. These findings from the BENEFIT (BEtaferon in Newly Emerging multiple sclerosis For Initial Treatment) studies* were presented today at the American Academy of Neurology's 59th Annual Meeting in Boston, Massachusetts.
德国拜耳先灵制药今日公布了一组残疾状态扩展评分表(EDSS)的数据，数据表明，与那些延期治疗的患者相比，在3年多时间里，使用倍泰龙（interferon beta-1b ，Betaferon®）对首发拟诊多发性硬化(MS)患者进行即刻治疗能明显使该病造成永久性神经损伤的风险降低40%。这组源于BENEFIT（倍泰龙在新发多发性硬化的最初治疗）临床研究的数据将会在美国马萨诸塞州波士顿美国神经学会第59届年会上公布。
"Some patients have already developed significant neurological damage when they first present with signs of MS, which can lead to accumulated disability later in life. The BENEFIT results clearly show that immediate treatment with Betaferon® initiated after the first clinical event can significantly reduce that damage, which could translate into a greater delay in the time it takes for patients to suffer from the debilitating consequences of MS," said Dr. Mark S. Freedman, Professor of Neurology at the University of Ottawa and investigator of the study. "This is a truly novel finding that has not yet been demonstrated for any other immunomodulatory MS treatment, and underscores the urgent need to treat patients early rather than waiting for further signs of MS to develop. Physicians and patients should consider these unprecedented findings when making treatment decisions."
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-09-28 11:44
医学,生命科学网